Annual EBIT
-$36.90 M
+$45.09 M+55.00%
31 December 2023
Summary:
Xeris Biopharma Holdings annual earnings before interest & taxes is currently -$36.90 million, with the most recent change of +$45.09 million (+55.00%) on 31 December 2023. During the last 3 years, it has risen by +$43.70 million (+54.22%). XERS annual EBIT is now -179.36% below its all-time high of -$13.09 million.XERS EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$11.28 M
-$4.98 M-79.21%
30 September 2024
Summary:
Xeris Biopharma Holdings quarterly earnings before interest & taxes is currently -$11.28 million, with the most recent change of -$4.98 million (-79.21%) on 30 September 2024. Over the past year, it has dropped by -$5.60 million (-98.52%). XERS quarterly EBIT is now -142.55% below its all-time high of -$4.65 million, reached on 31 March 2017.XERS Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$35.82 M
-$5.60 M-18.52%
30 September 2024
Summary:
Xeris Biopharma Holdings TTM earnings before interest & taxes is currently -$35.82 million, with the most recent change of -$5.60 million (-18.52%) on 30 September 2024. Over the past year, it has increased by +$3.37 million (+8.60%). XERS TTM EBIT is now -670.42% below its all-time high of -$4.65 million, reached on 31 March 2017.XERS TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XERS EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +55.0% | -98.5% | +8.6% |
| 3 y3 years | +54.2% | +53.4% | +57.3% |
| 5 y5 years | +35.9% | +61.5% | +66.3% |
XERS EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +68.1% | -98.5% | +77.0% | -18.5% | +72.3% |
| 5 y | 5 years | at high | +69.0% | -98.5% | +77.0% | -18.5% | +72.3% |
| alltime | all time | -179.4% | +69.0% | -142.6% | +77.0% | -670.4% | +72.3% |
Xeris Biopharma Holdings EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$11.28 M(+79.2%) | -$35.82 M(+18.5%) |
| June 2024 | - | -$6.29 M(-45.9%) | -$30.22 M(-20.3%) |
| Mar 2024 | - | -$11.64 M(+76.2%) | -$37.92 M(+2.8%) |
| Dec 2023 | -$36.90 M(-55.0%) | -$6.61 M(+16.3%) | -$36.90 M(-5.9%) |
| Sept 2023 | - | -$5.68 M(-59.4%) | -$39.19 M(-24.2%) |
| June 2023 | - | -$13.99 M(+31.7%) | -$51.69 M(-15.0%) |
| Mar 2023 | - | -$10.62 M(+19.3%) | -$60.78 M(-24.7%) |
| Dec 2022 | -$81.98 M(-29.0%) | -$8.90 M(-51.0%) | -$80.76 M(-33.2%) |
| Sept 2022 | - | -$18.18 M(-21.2%) | -$120.85 M(-4.8%) |
| June 2022 | - | -$23.08 M(-24.6%) | -$126.88 M(-2.0%) |
| Mar 2022 | - | -$30.60 M(-37.5%) | -$129.53 M(+12.1%) |
| Dec 2021 | -$115.55 M(+43.4%) | -$48.99 M(+102.4%) | -$115.55 M(+37.9%) |
| Sept 2021 | - | -$24.21 M(-5.9%) | -$83.82 M(+14.4%) |
| June 2021 | - | -$25.72 M(+54.8%) | -$73.28 M(+5.4%) |
| Mar 2021 | - | -$16.62 M(-3.7%) | -$69.53 M(-13.7%) |
| Dec 2020 | -$80.59 M | -$17.27 M(+26.3%) | -$80.59 M(-15.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | -$13.67 M(-37.8%) | -$95.33 M(-14.1%) |
| June 2020 | - | -$21.97 M(-20.7%) | -$110.99 M(-9.3%) |
| Mar 2020 | - | -$27.68 M(-13.5%) | -$122.35 M(+2.9%) |
| Dec 2019 | -$118.88 M(+106.6%) | -$32.01 M(+9.1%) | -$118.88 M(+11.9%) |
| Sept 2019 | - | -$29.33 M(-12.0%) | -$106.23 M(+16.8%) |
| June 2019 | - | -$33.32 M(+37.6%) | -$90.93 M(+29.8%) |
| Mar 2019 | - | -$24.21 M(+25.0%) | -$70.03 M(+21.7%) |
| Dec 2018 | -$57.53 M(+116.7%) | -$19.36 M(+38.0%) | -$57.53 M(+21.6%) |
| Sept 2018 | - | -$14.03 M(+12.9%) | -$47.32 M(+15.9%) |
| June 2018 | - | -$12.43 M(+6.1%) | -$40.81 M(+21.4%) |
| Mar 2018 | - | -$11.72 M(+28.1%) | -$33.62 M(+26.6%) |
| Dec 2017 | -$26.55 M(+101.0%) | -$9.14 M(+21.5%) | -$26.55 M(+52.5%) |
| Sept 2017 | - | -$7.53 M(+43.9%) | -$17.41 M(+76.2%) |
| June 2017 | - | -$5.23 M(+12.5%) | -$9.88 M(+112.5%) |
| Mar 2017 | - | -$4.65 M | -$4.65 M |
| Dec 2016 | -$13.21 M | - | - |
FAQ
- What is Xeris Biopharma Holdings annual earnings before interest & taxes?
- What is the all time high annual EBIT for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings annual EBIT year-on-year change?
- What is Xeris Biopharma Holdings quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings quarterly EBIT year-on-year change?
- What is Xeris Biopharma Holdings TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings TTM EBIT year-on-year change?
What is Xeris Biopharma Holdings annual earnings before interest & taxes?
The current annual EBIT of XERS is -$36.90 M
What is the all time high annual EBIT for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high annual earnings before interest & taxes is -$13.09 M
What is Xeris Biopharma Holdings annual EBIT year-on-year change?
Over the past year, XERS annual earnings before interest & taxes has changed by +$45.09 M (+55.00%)
What is Xeris Biopharma Holdings quarterly earnings before interest & taxes?
The current quarterly EBIT of XERS is -$11.28 M
What is the all time high quarterly EBIT for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high quarterly earnings before interest & taxes is -$4.65 M
What is Xeris Biopharma Holdings quarterly EBIT year-on-year change?
Over the past year, XERS quarterly earnings before interest & taxes has changed by -$5.60 M (-98.52%)
What is Xeris Biopharma Holdings TTM earnings before interest & taxes?
The current TTM EBIT of XERS is -$35.82 M
What is the all time high TTM EBIT for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high TTM earnings before interest & taxes is -$4.65 M
What is Xeris Biopharma Holdings TTM EBIT year-on-year change?
Over the past year, XERS TTM earnings before interest & taxes has changed by +$3.37 M (+8.60%)